Literature DB >> 29555966

Triple-negative breast cancers - a panoply of cancer types.

Fresia Pareja1, Jorge S Reis-Filho2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29555966     DOI： 10.1038/s41571-018-0001-7

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  14 in total

1.  Prognostic value of using glucosylceramide synthase and cytochrome P450 family 1 subfamily A1 expression levels for patients with triple-negative breast cancer following neoadjuvant chemotherapy.

Authors:  Jiannan Liu; Shuhua Wang; Congcong Wang; Xiangshuo Kong; Ping Sun
Journal:  Exp Ther Med       Date:  2021-01-22       Impact factor: 2.447

2.  Molecular determinants of drug response in TNBC cell lines.

Authors:  Nathan M Merrill; Eric J Lachacz; Nathalie M Vandecan; Peter J Ulintz; Liwei Bao; John P Lloyd; Joel A Yates; Aki Morikawa; Sofia D Merajver; Matthew B Soellner
Journal:  Breast Cancer Res Treat       Date:  2019-10-26       Impact factor: 4.872

3.  Predictive markers of endocrine response in breast cancer.

Authors:  Duniya Mosly; Arran Turnbull; Andrew Sims; Carol Ward; Simon Langdon
Journal:  World J Exp Med       Date:  2018-08-30

4.  Knockdown of nucleophosmin 1 suppresses proliferation of triple-negative breast cancer cells through activating CDH1/Skp2/p27kip1 pathway.

Authors:  Yingsheng Xiao; Jianling Zhu; Chunyan Peng; Weiquan Liang; Haoyu Lin
Journal:  Cancer Manag Res       Date:  2018-12-21       Impact factor: 3.989

Review 5.  Triple-negative breast cancer: recent treatment advances.

Authors:  Alice R T Bergin; Sherene Loi
Journal:  F1000Res       Date:  2019-08-02

6.  Methylation-dependent MCM6 repression induced by LINC00472 inhibits triple-negative breast cancer metastasis by disturbing the MEK/ERK signaling pathway.

Authors:  Guoli Shao; Xulong Fan; Pusheng Zhang; Xuewen Liu; Lei Huang; Shufeng Ji
Journal:  Aging (Albany NY)       Date:  2021-02-26       Impact factor: 5.682

Review 7.  The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors.

Authors:  Lorenzo Di Spazio; Melania Rivano; Luca Cancanelli; Marco Chiumente; Daniele Mengato; Andrea Messori
Journal:  Cureus       Date:  2022-01-09

Review 8.  Immune Effect of Active Components of Traditional Chinese Medicine on Triple-Negative Breast Cancer.

Authors:  Wenjie Zhao; Jinhua Liu; Yaqun Li; Zichao Chen; Dongmei Qi; Zhen Zhang
Journal:  Front Pharmacol       Date:  2021-12-03       Impact factor: 5.810

9.  Nanoparticles Loaded with the BET Inhibitor JQ1 Block the Growth of Triple Negative Breast Cancer Cells In Vitro and In Vivo.

Authors:  Valentina Maggisano; Marilena Celano; Rocco Malivindi; Ines Barone; Donato Cosco; Catia Mio; Chiara Mignogna; Salvatore Panza; Giuseppe Damante; Massimo Fresta; Sebastiano Andò; Diego Russo; Stefania Catalano; Stefania Bulotta
Journal:  Cancers (Basel)       Date:  2019-12-30       Impact factor: 6.639

10.  Molecular analyses of triple-negative breast cancer in the young and elderly.

Authors:  Mattias Aine; Ceren Boyaci; Johan Hartman; Jari Häkkinen; Shamik Mitra; Ana Bosch Campos; Emma Nimeus; Anna Ehinger; Johan Vallon-Christersson; Åke Borg; Johan Staaf
Journal:  Breast Cancer Res       Date:  2021-02-10       Impact factor: 6.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.